Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21530663 | 0.86 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL21530645 | 0.83 | ADORA2A (1.00) | ADORA2AALDH1A1SMN1; SMN2ADORA2B | |
| SCHEMBL21530720 | 0.81 | ADORA2A (1.00) | ADORA2AALDH1A1SMN1; SMN2ADORA2B | |
| SCHEMBL21530653 | 0.79 | ADORA2A (1.00) | ADORA2AALDH1A1SMN1; SMN2ADORA2BKDM4E | |
| SCHEMBL561761 | 0.77 | ADORA2A (0.63) | ADORA2AALDH1A1TSHRADORA2BKDM4E | |
| SCHEMBL21530648 | 0.74 | ADORA2A (1.00) | ADORA2AALDH1A1SMN1; SMN2ADORA2B | |
| SCHEMBL561996 | 0.72 | ADORA2A (0.64) | ADORA2AADORA2B | |
| SCHEMBL562813 | 0.72 | ADORA2B (0.56) | ADORA2ATSHRADORA2B | |
| SCHEMBL21530664 | 0.71 | ADORA2A (0.56) | ADORA2AALDH1A1SMN1; SMN2TSHRKDM4E | |
| SCHEMBL562116 | 0.69 | ADORA2A (0.52) | ADORA2AALDH1A1SMN1; SMN2TSHRADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220510-B2 | Pyrrole tricyclic compounds as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2022-01-11 | — | — | US | claimed |
| US-20190337957-A1 | PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2019-11-07 | — | — | US | claimed |
| US-20220213112-A1 | PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| US-20220213112-A1 | PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| US-11220510-B2 | Pyrrole tricyclic compounds as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2022-01-11 | — | — | US | disclosed |
| US-11220510-B2 | Pyrrole tricyclic compounds as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2022-01-11 | — | — | US | disclosed |
| US-20190337957-A1 | PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2019-11-07 | — | — | US | disclosed |
| US-20190337957-A1 | PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337957-A1 | PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ALDH1A1 1049/4885SMN1; SMN2 2747/4885 |
| US-20220213112-A1 | PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ALDH1A1 1049/4885SMN1; SMN2 2747/4885 |
| US-11220510-B2 | Pyrrole tricyclic compounds as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ALDH1A1 1049/4885SMN1; SMN2 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.